Finasteride vs Dutasteride: 23 Hair Trial Edge for Dutasteride and Clinician Advice

Dutasteride suppresses DHT more completely than finasteride and produced larger hair-count gains in the best head-to-head trial available, but finasteride is the one the FDA has actually approved for male pattern hair loss. That gap between “works better in trials” and “officially cleared for this use” is the whole story of finasteride vs dutasteride. The real trade-off isn’t efficacy versus safety, since sexual side effect rates look statistically similar between the two. It’s proven, labeled use versus stronger, off-label potency.

Finasteride is FDA-indicated for men only. Women who are or may become pregnant must not handle crushed or broken finasteride tablets, due to the risk of harm to a male fetus. It can also cause sexual side effects (reduced libido, erectile dysfunction) in a minority of men, which usually resolve after stopping treatment. Discuss these risks with a physician before starting.

TL;DR:

• Dutasteride suppresses DHT more completely than finasteride, achieving up to 90 to 99% reduction in serum DHT compared to finasteride’s 70%.
• The 2016 trial shows dutasteride can produce nearly six times the hair count gains in six months, but long-term benefits and generalizability beyond specific populations remain uncertain.
• Both drugs have similar rates of sexual side effects, with no statistically significant difference in long-term reports, though the data are limited and scientific consensus is still evolving.
• Finasteride is FDA-approved for male pattern hair loss and has a well-established safety profile, while dutasteride is off-label and has a longer half-life that complicates discontinuation and pregnancy precautions.
• Switching from finasteride to dutasteride is advisable only after a full trial year of finasteride with little response, and should involve objective monitoring with photos and medical advice.

Table of Contents

• Finasteride vs Dutasteride: How Each Drug Blocks DHT
• What the Clinical Trials Actually Show
• Comparing Side Effects, PSA Changes, and Long-Term Safety
• Switching From Finasteride to Dutasteride: What to Expect
• Beyond Pills: Combination Therapy and Other Options
• How Rao Dermatology Approaches the Finasteride or Dutasteride Decision
• The Bottom Line on Finasteride vs Dutasteride
• What the Research Gets Right, and Where It Falls Short
• Ready to Talk to a Dermatologist About Hair Restoration?
• Sources
• FAQ

Finasteride vs Dutasteride: How Each Drug Blocks DHT

Both drugs target the same villain: dihydrotestosterone, or DHT, the hormone that shrinks hair follicles in genetically susceptible scalps. They just don’t do it the same way, and that difference explains almost everything else in this comparison.

DHT gets made when an enzyme called 5-alpha reductase converts testosterone into its more potent cousin. There are two main isoenzyme types that matter here. Type 1 operates mostly in the skin, liver, and sebaceous glands. Type 2 dominates in the hair follicles and prostate. Finasteride blocks only type 2. Dutasteride blocks both type 1 and type 2, which is why dermatologists call it a “dual” inhibitor.

That structural difference shows up directly in the bloodstream. Comparative pharmacology data suggests finasteride reduces serum DHT by roughly 70%, while dutasteride can push that suppression up toward 90 to 99% depending on the study and dosing. That’s not a marginal edge. It’s close to total DHT knockdown versus a partial one.

Key pharmacology differences:

• Enzyme targets: Finasteride inhibits type 2 5-alpha reductase only; dutasteride inhibits both type 1 and type 2.
• DHT suppression: Finasteride reduces serum DHT by around 70%; dutasteride reaches up to 90 to 99% in some measures.
• Half-life: Finasteride clears in about 5 to 6 hours; dutasteride’s half-life runs into weeks, meaning it lingers in the body long after the last dose.
• Steady-state timing: Finasteride reaches stable blood levels within days; dutasteride can take months to reach full steady-state suppression.

Pro Tip: That long half-life cuts both ways. It means dutasteride keeps working even if you miss a dose here and there, but it also means side effects, if they occur, can take much longer to resolve after you stop taking it.

The half-life gap matters more than most patients realize. If you want to father a child or need to clear a drug from your system before a procedure, finasteride’s short half-life makes that far more predictable than dutasteride’s long tail.

What the Clinical Trials Actually Show

The most cited head-to-head comparison is a 2016 randomized trial that put dutasteride 0.5 mg daily against finasteride 1 mg daily over 24 weeks. The results were not subtle.

Patients on dutasteride went from a baseline hair count of 223 hairs per square centimeter to 246. Patients on finasteride moved from 227 to 231 over the same period. Do the subtraction and dutasteride delivered roughly a 23-hair-per-square-centimeter gain against finasteride’s 4. That’s close to a sixfold difference in measured regrowth over half a year.

A 2024 systematic review comparing the two drugs in hair regrowth concluded that dutasteride’s dual-enzyme blockade translates into consistently larger increases in hair density across the studies examined, reinforcing the pharmacologic logic that more complete DHT suppression produces more measurable follicle response.

That’s a meaningful signal, but it comes with real limits worth naming before anyone assumes dutasteride is simply the better drug in every case.

• Many of the foundational dutasteride hair-loss trials enrolled largely Asian cohorts, which raises questions about how well the results generalize across different populations and hair types.
• Follow-up periods in most trials run 24 to 48 weeks. Hair loss and its treatment play out over years, not months, so long-term durability data is thinner than the short-term numbers suggest.
• Trial hair counts are measured with standardized photography and phototrichograms under controlled conditions. Real-world results, measured by how your hair actually looks in a bathroom mirror, tend to be less dramatic and slower to notice.

None of that erases dutasteride’s advantage. It just means the size of that advantage in a controlled 24-week trial isn’t a guarantee of the same margin over five years of daily life.

Finasteride’s own track record, meanwhile, is well established and less flashy but still solid. The American Academy of Dermatology notes that finasteride slows further hair loss in about 80 to 90% of men who take it, with visible improvement typically showing up around four to six months in. That’s not a dramatic transformation for most patients. It’s a plateau, then a slow reversal of miniaturization, which is exactly what a type 2 selective inhibitor should be expected to do.

The practical read: dutasteride tends to win on raw hair-count numbers in trials, finasteride wins on decades of real-world use and an FDA label that actually says “androgenetic alopecia” on it. Neither fact cancels the other out. They just answer different questions, and which one matters more depends on whether you’re weighing peak potency or regulatory certainty.

Comparing Side Effects, PSA Changes, and Long-Term Safety

The sexual side effect question is the one most patients actually lie awake worrying about, so start there. A 2019 systematic review and meta-analysis pooling data across multiple studies found no statistically significant difference in rates of altered libido, erectile dysfunction, or ejaculation disorders between dutasteride and finasteride. Despite dutasteride’s much stronger DHT suppression, it doesn’t appear to translate into meaningfully more sexual side effects in the pooled trial data.

That finding deserves a caveat, and a fair comparison has to state it plainly for both drugs equally. Meta-analyses capture what gets measured in structured trials. Postmarketing reports and patient case series describe a smaller subset of men who report sexual side effects persisting well after they stopped either drug. Randomized trials haven’t established that this persistence is actually caused by the medication rather than age, other health conditions, or other medications a patient happens to be on at the same time. The uncertainty here applies to finasteride and dutasteride alike. Neither drug gets a pass and neither gets singled out as riskier based on current evidence.

What the numbers say about prostate risk:

• The REDUCE trial found a higher incidence of aggressive, high-grade (Gleason 8–10) prostate cancer in men taking dutasteride versus placebo, at 1.0% versus 0.5%.
• The PCPT trial found a similar pattern with finasteride in older men, at 1.8% versus 1.1% for placebo, as reported in Proscar’s FDA label.
• Both drugs also lower PSA readings by roughly half, which means a doctor tracking prostate health needs to double a patient’s PSA value to interpret it against normal reference ranges.

Those prostate numbers come from trials that enrolled older men at baseline prostate cancer risk, not from the younger population usually seeking finasteride or dutasteride for hair loss, so treat the absolute percentages as context, not a precise personal risk. What they justify is a straightforward conversation with a physician about PSA baselines, especially for men over 50 or anyone with a family history of prostate cancer.

Pro Tip: If you’re started on either drug in your 20s or 30s purely for hair loss, mention it to your primary care doctor before your first PSA screening years down the road. A screening PSA that looks reassuringly low might actually be masking a real problem if the lab doesn’t know to adjust for the medication.

Pregnancy risk is where the caution has to be absolute rather than probabilistic. Both drugs carry a Category X-type risk for male fetuses because they block the DHT signaling needed for normal male genital development. Women who are pregnant or may become pregnant should not handle broken or crushed tablets from either medication, and men taking either drug should discuss contraception timing with a partner who could become pregnant. Finasteride’s short half-life clears from semen faster than dutasteride’s, which matters for couples actively trying to conceive.

Before starting either drug, a baseline conversation should cover personal and family prostate cancer history, current PSA if age-appropriate, sexual health history, and family planning status. Any new or worsening sexual side effect, mood change, or breast tenderness should get reported back to the prescribing clinician rather than quietly tolerated.

Switching From Finasteride to Dutasteride: What to Expect

Switching makes sense mainly in one scenario: a patient has been on a properly dosed finasteride regimen for a genuinely adequate trial, usually 12 months or longer, and the response has plateaued or disappointed relative to expectations. Switching after six weeks because nothing has changed yet is premature. Both drugs work slowly.

1. Confirm an adequate trial happened first. Six months is the minimum to judge finasteride; a full year gives a clearer picture, since hair growth cycles run in months, not weeks.
2. Decide on direct substitution versus a washout period. Most clinicians move patients straight from finasteride to dutasteride without a gap, since dutasteride’s dual action naturally supersedes finasteride’s narrower one. A washout is rarely necessary from an efficacy standpoint, though it may be discussed case by case.
3. Reset expectations on timeline. Because dutasteride’s half-life is measured in weeks rather than hours, it takes longer to reach steady-state DHT suppression. Visible changes after switching often take four to six months to show up, similar to or slightly longer than the original finasteride timeline.
4. Expect possible early shedding. A temporary increase in shedding within the first few weeks of switching can reflect follicles cycling out of a resting phase before regrowth begins. It’s usually not a sign the switch failed.
5. Track progress objectively, not by feel. Standardized photos taken in the same lighting and angle, plus a dermatologist’s periodic assessment, catch real change far more reliably than a daily mirror check.

Pro Tip: Take your baseline photos before you switch, not after. Patients almost never remember what their hairline looked like six months ago, and without a true “before” shot, it’s easy to talk yourself into thinking nothing has changed.

Before making the switch official, walk through a short checklist: confirm pregnancy precautions with any partner, revisit PSA baseline discussion if you’re over 50, and get honest informed consent that persistent sexual side effects, while statistically similar between the two drugs, remain an area of real scientific uncertainty rather than a fully closed question.

Beyond Pills: Combination Therapy and Other Options

Neither finasteride nor dutasteride works in isolation as well as it works alongside other treatments, and most dermatology practices treat oral 5-alpha reductase inhibitors as one piece of a larger plan rather than a standalone fix.

• Topical minoxidil works through a completely different mechanism, extending the growth phase of hair follicles rather than blocking DHT, which is why the Academy’s combination guidance often pairs it with an oral inhibitor for a broader effect.
• PRP therapy injects a patient’s own concentrated platelets into the scalp to stimulate follicle activity, and clinics frequently layer it onto oral therapy for patients with more advanced miniaturization, as outlined in this overview of PRP treatment for hair loss.
• Low-level laser therapy (LLLT) offers a lower-intensity, at-home adjunct with a more modest evidence base, generally used to support rather than replace drug therapy.
• Surgical hair restoration becomes the relevant conversation once miniaturization has progressed too far for medical therapy alone to reverse, typically after other options have been tried and plateaued.

Multimodal therapy matters most for patients with extensive miniaturization at diagnosis, since a single mechanism rarely reverses advanced thinning on its own. It also matters for female pattern hair loss, where finasteride and dutasteride are used off-label and typically alongside other treatments rather than as first-line monotherapy, and for scarring alopecias, where oral inhibitors play a smaller role than anti-inflammatory management.

How Rao Dermatology Approaches the Finasteride or Dutasteride Decision

Choosing between finasteride and dutasteride isn’t a coin flip, and it shouldn’t be a decision made from a questionnaire on a website. Rao Dermatology’s dermatology providers evaluate hair loss patients the way any medical prescription decision deserves: with a documented history, an honest look at expectations, and a follow-up plan that actually gets used.

In practice, most patients start on finasteride first. It has the FDA-labeled indication for male pattern hair loss, a longer real-world track record, and a shorter half-life that gives more flexibility if side effects or family planning become a factor. Dutasteride enters the conversation off-label when finasteride has been given a genuine trial and the response has fallen short of what the patient and clinician agreed was reasonable.

Baseline evaluation includes a personal and family medical history, a review of prostate cancer risk factors, and a PSA discussion for men in the age range where that screening matters. Follow-up isn’t optional. Photos at baseline and reassessment at defined intervals, generally in the six-to-twelve-month range, are how a clinician actually knows whether a treatment is working rather than guessing. Readers who want that kind of clinician-led evaluation and prescription management can explore hair restoration services built around exactly this process.

The Bottom Line on Finasteride vs Dutasteride

Dutasteride suppresses DHT more completely and produced larger hair-count gains in the strongest trial data available. Finasteride carries the FDA-labeled indication and decades of accumulated real-world use, which counts for something no trial result alone can replace. Neither fact makes the other obsolete. It makes the choice depend on your specific situation.

Three next steps make that choice concrete: get evaluated by a dermatologist rather than self-prescribing off a forum recommendation, have an honest conversation about PSA baselines and reproductive plans before starting either drug, and set a measurable follow-up point, with photos at baseline and again around six months, so progress gets judged by evidence instead of impatience.

What the Research Gets Right, and Where It Falls Short

The evidence genuinely supports dutasteride’s pharmacologic edge. A dual-enzyme blockade that pushes DHT suppression toward 90 to 99% is going to outperform a single-enzyme inhibitor sitting around 70%, and the 2016 trial numbers back that up in measurable hair counts. Where the conventional online advice falls short is in treating that trial result as the whole answer. A 24-week study in a specific population isn’t the same as a guarantee of superior long-term outcomes for every patient, and it says nothing about the regulatory reality that finasteride, not dutasteride, is the one actually approved for this exact condition.

The bigger blind spot in most hair loss forums is the persistence question around sexual side effects. Pooled trial data shows no significant difference between the drugs, and that’s worth taking seriously rather than dismissing. But it shouldn’t be mistaken for certainty about the smaller number of men reporting lasting symptoms after stopping. Readers should prioritize an honest baseline conversation with a clinician over chasing the drug with the bigger headline number.

— Rao Dermatology

Ready to Talk to a Dermatologist About Hair Restoration?

Deciding between finasteride and dutasteride, or figuring out whether either one is right for you at all, works better as a medical conversation than a guessing game with online reviews. Providers evaluate your hair loss pattern, medical history, and treatment goals in person or via telehealth, then manage the prescription and monitoring that a safe long-term plan actually requires.

A clinician-led visit catches what self-treatment misses: an accurate baseline PSA discussion if it’s relevant to your age, a real assessment of how advanced your miniaturization is, and a follow-up schedule that tells you objectively whether your treatment is working instead of leaving you to guess in the mirror. Some dermatology practices also offer PRP and other procedural options for patients whose hair loss needs more than a pill alone.

If you’re ready to get a personalized evaluation, visit the hair restoration services page to learn more and schedule a consultation.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

Sources

• Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male pattern hair loss (2016 trial)
• Systematic review and meta-analysis comparing dutasteride and finasteride safety (2019)
• American Academy of Dermatology: male pattern hair loss treatment (finasteride notes)
• PROSCAR (finasteride) FDA label — safety sections (2026)

FAQ

Is It Worth Switching From Finasteride to Dutasteride?

It can be worth considering if you’ve completed a proper finasteride trial of at least six to twelve months and your results have plateaued below expectations. Dutasteride’s dual-enzyme action produced larger hair-count gains in the best available head-to-head trial, but it remains off-label for hair loss, so the switch should happen with a clinician who can set clear follow-up checkpoints.

Can Dutasteride Cause Permanent Erectile Dysfunction?

Pooled trial data shows no statistically significant difference in erectile dysfunction rates between dutasteride and finasteride, and randomized trials haven’t proven that either drug causes lasting dysfunction after stopping. A smaller number of postmarketing reports describe persistent symptoms, but confounding factors like age and other medications make causation hard to establish, so this remains an open question rather than a settled one.

Is Dutasteride Feminizing?

No, dutasteride does not cause feminization at the doses used for hair loss. It blocks DHT production rather than raising estrogen levels, and reported side effects are limited to sexual function changes and, rarely, breast tenderness, not feminizing physical changes.

Why Is Dutasteride Not FDA Approved for Hair Loss?

Dutasteride is FDA approved for benign prostatic hyperplasia, but it has never completed the specific approval pathway for male pattern hair loss in the United States, which is why dermatologists prescribe it off-label for that purpose. Finasteride, by contrast, holds the FDA-labeled indication for androgenetic alopecia, which is one reason many clinicians start patients on finasteride before considering dutasteride.

Recommended

• Female Hair Loss Treatment for Women
• PRP Treatment for Hair Loss: What to Expect from Platelet-Rich Plasma Therapy
• Dermatology Best Practices 2026: A Clinician’s Guide